Jia Jenny Liu

Jia (Jenny) Liu

Medical Oncologist

The Kinghorn Cancer Centre

Australia, Sydney

Present Title & Affiliation

  • Staff Specialist, Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital Sydney
  • Senior Research Officer, ProCan Oncology, Children’s Medical Research Institute
  • Honorary Research Officer, Translational Oncology Program, Garvan Institute of Medical Research
  • Conjoint Senior Lecturer, St Vincent’s Clinical School, University of New South Wales
  • Adjunct Research Fellow, School of Public Health and Preventive Medicine, Monash University / Melanoma & Skin Cancer Trials
QualificationField / SpecializationInstitutionLocation

Education & Training
FRACPInternal Medicine & Medical OncologyRoyal Australasian College of PhysiciansAustralia
BMed, MD (Distinction, University Medal)MedicineUniversity of New South WalesSydney
PhDCancer Biology / EpigeneticsUniversity of New South WalesSydney
BSc(Med) Hons (Class I)Cancer Biology / EpigeneticsUniversity of New South WalesSydney

Professional Positions & Employment
Staff Specialist Medical OncologistMedical OncologyThe Kinghorn Cancer CentreSenior early-phase trials clinician
Senior Research OfficerProCan OncologyCMRIProteomics-driven discovery
Honorary Research OfficerTranslational OncologyGarvan InstituteBiomarker-driven oncology research
Conjoint Senior LecturerClinical SchoolUNSWMedical student & trainee teaching
Adjunct Research FellowPublic Health & Preventive MedicineMonash UniversityMelanoma & skin cancer trials
Medical Oncology FellowEarly Phase Clinical TrialsWestmead & Blacktown HospitalsFellowship training
Advanced Trainee
Medical OncologyChris O’Brien Lifehouse; ConcordSpecialist training
Basic Physician Trainee
Internal MedicineRoyal Prince Alfred HospitalCore training
Resident Medical Officer
Radiation Oncology & HaematologyRPAHRotational resident
Intern
Medicine & SurgeryRPAHInternship
Research Officer
Radiation OncologyChris O'Brien LifehouseLab-based oncology research
Conjoint Associate Lecturer
Clinical SchoolUNSWUndergraduate education

Hospital Appointments
Medical Oncologist
Medical OncologySt Vincent’s Hospital SydneyEarly-phase trials
MDT Member
Head & Neck CancerSVHActing chair as required
Skin CancerSVHMultidisciplinary care
Supervisor
Basic Physician TraineesSVHInpatient oncology
Overseas Trained PhysiciansSVHClinical supervision

Institutional Leadership Activities
Deputy Convenor
ACORD Protocol Development Workshop; mentoring APAC clinical trialistsACORD
Program Chair
National Oncology Mentorship ProgramMOGA
Executive Committee Member
Leadership in national oncology policy & educationMOGA
Advisory Contributor
Head & neck and skin cancer clinical protocolseviQ
EMCR Committee Member
Faculty and professional developmentUNSW
Supervisor & Mentor
Oncology trainees, PhD and MD candidatesSVH / UNSW

Institutional Administrative Activities
Chair / Member MDT
Head & Neck Cancer MDT, Skin Cancer MDTSVH
Oncology Trainee Supervisor
Medical Oncology rotationSVH
Educator
Lectures, tutorials, OSCEsUNSW
Curriculum Contributor
Medicine program redesignUNSW
Leadership Training
AVANT, HETI programsNational

Extramural Institutional Committee Activities
AACR Clinical Trials Committee
MemberEarly-phase drug development
ESMO Tumor Agnostic Scientific Committee
MemberBiomarker-guided oncology
MOGA Executive Committee
MemberNational oncology leadership
ACORD Steering Committee
MemberProtocol development training
UNSW Cancer Conference
Steering CommitteeScientific program development
WIN Consortium
General Assembly MemberGlobal early-phase oncology
NSW Early Phase Trials Alliance
MemberTrial network coordination
Scientific Reviewer
AACR, ESMO, COSA, UNSW, grant panelsPeer review

Professional Organizations & Society Memberships
American Society of Clinical Oncology (ASCO)
Member
European Society for Medical Oncology (ESMO)
Member
American Association for Cancer Research (AACR)
Member
Medical Oncology Group of Australia (MOGA)
Executive Member
Clinical Oncology Society of Australia (COSA)
Member
Psycho-Oncology Cooperative Research Group
Member
Melanoma and Skin Cancer Trials
Member
Clinical Trials Australia
Member
Worldwide Innovative Network (WIN)
Member
NSW Early Phase Trials Alliance (NECTA)
Member

Honors & Awards
University Medal (Medicine)
UNSWHighest academic distinction
Scholar Award
UNSWAcademic excellence
Best Young Researcher Award
MOGAEarly-career excellence
Rapid Oral Presentation Winner
St Vincent’s Health Innovation PrecinctEarly-phase trials research
Engagement & Leadership Award
UNSWAcademic leadership
Travel Awards & Scholarship Grants
Multiple national organizationsResearch excellence
Clinical & academic prizes (Pathology, Surgery, Medicine, GP)
UNSWMultiple distinctions

Teaching & Supervision
Lecturer & Tutor
Medical students, OSCE, clinical skillsUNSW, USyd
Mentor
National Oncology Mentorship ProgramMOGA
Supervisor
Oncology fellows, physician traineesSVH
Workshop Faculty
Communication skills, career developmentUNSW
3MT Judge
University finalsUNSW
Curriculum Contributor
Medicine program redesignUNSW

Research Supervision
PhD Candidates
Proteomics, ADCs, trial equity, epigenetic therapiesUNSW, CMRI, Garvan
Honours Students
Early-phase trial toxicities; translational oncologyUNSW
MD / Research Students
CUP proteomics, immunotherapy-exercise interactionsUNSW, USyd
MD / Research Students
CUP proteomics, immunotherapy-exercise interactionsUNSW, USyd
Medical Oncology Fellows
Investigator-led trialsSVH
Collaborative Teams
Proteomics, ctDNA, solid tumour translational scienceCMRI / UNSW

Conference Leadership & Steering
Committee Member
AACR Annual Meeting Clinical Trials Program
Scientific Committee
ESMO Congress, Tumor-Agnostic Track
Steering Committee

ACORD Protocol Development Workshop
Co-Chair

COSA Annual Scientific Meeting
Scientific Committee

UNSW Cancer Conference
Session Chair / Moderator

National & international oncology meetings
Steering Committee
DISCO (Dose Individualisation of Cancer Drugs)

Conference Presentations – Selected
International Invited
ESMO CongressADC & IO tumour-agnostic development
ESMO TAT AsiaDose optimisation in novel combinations
ASTRO, AACR, SITCBiomarkers, early-phase trials
National Invited
MOGA, COSA, CTIONeoadjuvant trials, career pathways
Local Invited
SVH & UNSW SymposiaTrials, FCR, supportive oncology
Proffered Abstracts
ESMO, ASCO, AACR, SITCEarly-phase trial data, ctDNA, ERAP1, IVX037

Media, Podcasts & Public Engagement
National TV Interview
ABC NewsDisability & diversity in clinical trials
National TV Interview
ABC NewsDisability & diversity in clinical trials
National Radio
ABC National RadioFear of cancer recurrence
Podcast Guest
Oncology Journal Club; Oncology for the Inquisitive MindEarly-phase trials; mentorship
Podcast Host
NECTA – Dangerous Ideas in Drug DevelopmentEarly drug development
Public Feature
ABCClinician wellbeing, burnout

Peer-Reviewed Journal Articles

  1. Liu J*, Yang J*, Sun Y*, Gong J*, Yue J, Pan Y, et al.
    CLDN18.2-targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: A phase 1 trial.
    Nature Medicine (Impact Factor 58.7). 2025 Jul 16:1–9. doi:10.1038/s41591-025-03783-8.
  2. Cai Z*, Boys EL*, Noor Z*, Aref A, Xavia D, Lucas N, Williams SG, Koh HMS, Poulos RC, Wu Y, Dausmann M, MacKenzie KL, Aguilar-Mahecha A, Armengol C, Barranco MM, Basik M, Bowman ED, Clifton-Blig RJ, Connolly EA, Cooper WA, Dalal B, DeFazio A, Filipitis M, Flynn PJ, Graham JD, George J, Gill AJ, Gnant M, Habib R, Harris CC, Harvey K, Horvath LG, Jackson C, Kohonen-Corish MRJ, Lim E, Liu J, Long G, Lord RV, Mann GJ, McCaughan GW, Morgan L, Murphy LC, et al.
    Federated deep learning enables cancer subtyping by proteomics.
    Cancer Discovery (IF 39.4). 2025 Jun 9. doi:10.1158/2159-8290.CD-24-1488.
  3. Jackson C*, Liu J* (equal 1st authors), Liu HY, Williams SG, Anees A, Noor Z, et al.
    A proteomic signature for HPV-associated oropharyngeal squamous cell carcinoma predicts recurrence risk.
    Cancer Research Communications. 2025 Apr 1;5(4):580–593. doi:10.1158/2767-9764.CRC-23-0460.
  4. Nindra U, Shivasabesan G, Mellor R, Ng W, Chua W, Karikios D, Richards B, Liu J.
    Final results of the National Oncology Mentorship Program 2023 and its impact on burnout and professional fulfilment.
    Internal Medicine Journal. 2025 Feb;55(2):233–240. doi:10.1111/imj.16574.
  5. Smith BA, Girgis A, Pearce A, Liu J, Shepherd H, Wu V, Garvey G, Kirsten L, Zakhary I, Ee C, Ewald D, Miller A, Shaw J.
    Clinical pathway for fear of cancer recurrence screening and stepped-care triage: A Delphi consensus process.
    Supportive Care in Cancer. 2024 Oct 7. doi:10.1007/s11764-024-01685-1.
  6. Boys EL, Gao B, Grimison P, Sutherland S, Mackenzie KL, Roger RR, Liu J.
    Clinical characteristics and outcomes of carcinoma of unknown primary: A retrospective multi-center analysis.
    Cancer Medicine. 2024;13(6):e7052. doi:10.1002/cam4.7052.
  7. Pham JP, Zdanska O, Selga S, Javier J, O’Grady A, Chin V, Forstner D, Hsu E, Liu J.
    Oncolytic viruses to augment PD-1 inhibition in metastatic cutaneous SCC.
    Journal der Deutschen Dermatologischen Gesellschaft. 2024 Jul;22(7):1016–1018. doi:10.1111/ddg.15423.
  8. Nindra U, Shivasabesan G, Mellor R, Chua W, Ng W, Karikios D, Richards B, Liu J.
    Evaluating systemic burnout in medical oncology via a national mentorship program.
    JCO Oncology Practice. 2024 Jan 30. doi:10.1200/OP.23.00469.
  9. Liu J, He S, Butow P, et al.
    Clinician-delivered intervention to reduce fear of recurrence in breast cancer survivors: CIFeR_2 Phase I/II results.
    Psycho-Oncology. 2023 Dec;32(12):1930–1938. doi:10.1002/pon.6249.
  10. Liu J, Serafimovska A, Butow P, Shaw J, McHardy CJ, Harris G, Butt Z, Beith J.
    Implementation study protocol for CIFeR_2 intervention to reduce fear of recurrence.
    BMC Medical Education. 2023;23:312. doi:10.1186/s12909-023-04279-0.
  11. Pham JP, Sivasubramaniam V, Gallagher R, Forstner D, Wong M, Liu J.
    Cemiplimab safety in metastatic cSCC with p-ANCA vasculitis.
    Journal of the European Academy of Dermatology & Venereology. 2023;37(3):e363–e365. doi:10.1111/jdv.18649.
  12. Serafimovaska A, Liu J, Beith JM, Butow P.
    Patients’ and oncologists’ perspectives on CIFeR intervention for fear of recurrence.
    Supportive Care in Cancer. 2021;29(12):7637–7646. doi:10.1007/s00520-021-06336-0.
  13. Liu J, Bui KT, Serafimovaska A, Kiely BE, Hui MN, Goodwin A, McNeil CM, Costa DSJ, Butow P, Beith JM.
    Clinician-led intervention for fear of recurrence (CIFeR) in breast cancer survivors.
    JCO Oncology Practice. 2021 Jun;17(6):e774–e784. doi:10.1200/OP.20.00799.
  14. Liu J, Wong K, Patanjali N, Boyer M, Kao S.
    Post-progression survival prolongation after pembrolizumab cessation in advanced NSCLC.
    Internal Medicine Journal. 2020;50(6):771–773. doi:10.1111/imj.14852.
  15. Goel S*, Liu J*, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Ashgari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J.
    LVEF decline after anthracyclines predicts trastuzumab cardiotoxicity: CATS study.
    JACC: Heart Failure. 2019;7(9):795–804. (Equal first author)
  16. Crabtree N, Mo S, Ong L, Jegathees T, Wei D, Fahey D, Liu J.
    Patient presentations at the Sydney Royal Easter Show (2012–2014).
    Prehospital and Disaster Medicine. 2017;32(2):1–8.
  17. Liu J, Ng D, Lee J, Stalley P, Hong A.
    Chest wall desmoid tumours treated with definitive radiotherapy: IMRT vs VMAT comparison.
    Radiation Oncology. 2016;11:34.
  18. Thoms JA, Knezevic K, Liu J, Glaros EN, Thai T, Qiao Q, et al.
    Mutation in Dhfr causes arrested hematopoiesis and vascular relaxation defects.
    Molecular and Cellular Biology. 2016;36(6):1222–1236.
  19. Youngson N, Lecomte V, Maloney CA, Leung P, Liu J, Hesson L, Luciani F, et al.
    Obesity-induced sperm DNA methylation changes reprogrammed in rat offspring.
    Asian Journal of Andrology. 2015;18(6):930–936.
  20. Liu J, Zhang M, Rose B, Veillard A, Jones D, Lee CS, Harnett G, Clark J, Elliott M, Milross C, Hong A.
    Ki67 has prognostic significance based on HPV status in OPSCC.
    Annals of Surgical Oncology. 2014;22(6):1893–1900.
  21. Simar D, Versteyhe S, Donkin I, Liu J, Hesson L, Nylander VC, Fossum A, Barrès R.
    DNA methylation alterations in B and NK cells in obesity and type 2 diabetes.
    Metabolism. 2014;63(9):1188–1197.
  22. Liu J, Hau E, Links M, Graham PH.
    Primary adenoid cystic carcinoma of the lung treated with chemoradiation and tamoxifen.
    Asia-Pacific Journal of Clinical Oncology. 2013;12(2):352–355.
  23. Liu J, Hesson LB, Ward RL.
    UHPLC-MS/MS for global DNA methylation and hydroxymethylation.
    Journal of Proteomics & Bioinformatics. 2013;S2:1–6.
  24. Hesson LB, Patil V, Sloane MA, Nunez AC, Liu J, Pimanda JE, Ward RL.
    MLH1 promoter nucleosome reassembly triggers resilencing after decitabine.
    PLoS Genetics. 2013;9(7):e1003636.
  25. Liu J, Hesson LB, Meagher AP, Bourke MJ, Hawkins NJ, Rand KN, Molloy PL, Pimanda JE, Ward RL.
    Folate species and association with global DNA methylation in colorectal mucosa.
    Cancer Prevention Research. 2012;5(7):921–929.
  26. Liu J, Pickford R, Meagher AP, Ward RL.
    Quantitative analysis of tissue folate using UHPLC-MS/MS.
    Analytical Biochemistry. 2011;411(2):210–217.

Reviews

  1. Shekar S, Hall A, Pham J, Crumbaker M, Liu J, Talmor B, Sim HW, Joshua AM.
    Systemic therapy efficacy in metastatic adrenocortical carcinoma.
    Endocrine Oncology. 2025 Aug 19.
  2. Liu J, Farrow M, Seymour L, Desai J, Ivy P, Koyoma T, et al.
    Global consortia and precision oncology: Accelerating early-phase clinical trials.
    Journal of Clinical Oncology. 2025 Feb 20;43(6):735–747. doi:10.1200/JCO-24-01534.
  3. Corry J, Brungs D, Liu J, McDowell L, Thornton R, Mar G, Nicholls T, Ooi EH.
    Unmet clinical needs in locally advanced head and neck cancer: Australian perspective.
    Asia-Pacific Journal of Clinical Oncology. 2025 Aug 21.
  4. El-Deiry WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, … Liu J, Lussier Y, Raynaud J, Batist G, Magidi S, Kurzrock R.
    Worldwide Innovative Network (WIN) Consortium: Next-generation precision oncology.
    Oncotarget. 2025 Mar 12;16:140–162.
  5. Pham JP, Staeger R, Joshua AM, Liu J, Da Silva IP, Dummer R, Goldinger SM.
    Immune checkpoint inhibitors in cutaneous oncology beyond melanoma.
    European Journal of Cancer. 2024;214:115121.
  6. Pham JP, Rodrigues A, Goldinger SM, Sim HW, Liu J.
    EGFR inhibitors in advanced cutaneous SCC: Systematic review and meta-analysis.
    Experimental Dermatology. 2024;33(1):e14978.
  7. Nindra U, Hurwitz J, Forstner D, Chin V, Gallagher R, Liu J.
    Systematic review of neoadjuvant and definitive immunotherapy in locally advanced HNSCC.
    Cancer Medicine. 2023;12(10):11234–11247.
  8. Boys EL, Liu J, Robinson PJ, Reddel RR.
    Mass spectrometry-based proteomics in cancer: Clinical applications.
    Proteomics. 2022;23(7–8):e2200238.
  9. Cai Z, Poulos RC, Liu J, Zhong Q.
    Machine learning for multi-omics integration in cancer.
    iScience. 2022;25(2):103798.
  10. Liu J, Goel S, Beith J.
    Trastuzumab-related cardiotoxicity: Current understanding.
    Translational Cancer Research. 2020;9(7):4052–4055.
  11. Liu J, Butow P, Beith J.
    Clinician interventions for fear of recurrence: Systematic review.
    Supportive Care in Cancer. 2019;27(11):4055–4067.

For a complete and up-to-date list of publications, please refer to Dr. Liu’s ResearchGate profile: https://www.researchgate.net/profile/Jia-Liu-187?ev=hdr_xprfÂ